Editor's Picks

There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.

Sanofi-Aventis

Sanofi-Aventis

  1. Vernalis shares rise 28% after US cold medicine deal
    Guardian Unlimited logo Guardian Unlimited 1 day ago
    Woman Sneezing

    Shares in Vernalis have surged after the biotechnology firm sealed a key deal with US company Tris Pharma to develop slow-release cough and cold medicines. The arrangement cheered investors, who pledged three times the company's £20m market value in a fu

  2. WHO’s nod awaited on Shantha’s Shan 5
    MyDigitalFC.com | Financial Chronicle logo MyDigitalFC.com | Financial Chronicle 1 day ago

    Shantha Biotech, an arm of the global pharma major Sanofi Aventis, is hopeful of launching its flagship pentavalent vaccine, Shan 5, by the end of 2013. The vaccine, which the company expected big returns from, was suspended by the World Health Organisat

  3. Getty Images logo Getty Images 9 months ago
    SACRAMENTO, CA - MAY 16: (L-R) James Driscoll of the USA and riding for Jamis-Sutter Home leads the breakaway group infront of Laszlo Bodrogi of France and riding for Team Type 1-Sanofi Aventis, Ben Jacques-Maynes of the USA and riding for Bissell Cycling...

    SACRAMENTO, CA - MAY 16: (L-R) James Driscoll of the USA and riding for Jamis-Sutter Home leads the breakaway group infront of Laszlo Bodrogi of France and riding for Team Type 1-Sanofi Aventis, Ben Jacques-Maynes of the USA and riding for Bissell Cycling... View Photo »

  4. This is one of those treatments that have been tossed around like a hot potato for the past decade or more ... For example, some rights to DiaPep277 were acquired by the company known as Aventis (which became Sanofi Aventis back in 1997), although full rights were reported to be acquired by the predeces...
    SOURCE: Diabetes Mine 3 weeks ago
  5. Total Plans Production Increase, Asset Sales as Profits Rise
    Bloomberg.com logo Bloomberg.com 1 day ago
    Total SA Chief Executive Officer Christophe de Margerie

    Total SA (FP), Europe’s third-largest oil producer, posted a 7 percent increase in profit on higher crude prices and pledged to raise output and sell assets this year. Fourth-quarter profit, excluding changes in inventories and the value of a stake in Sa

  6. Mother tackles 'danger' drug
    Morning Star Online 1 day ago

    Emma Downes from Manchester believes Epilim's manufacturers, Sanofi Aventis, are not doing enough to warn the public of the dangers of the drug and so has taken matters into her own hands. Hundreds of mothers with children suffering from birth defects lo

  7. Apotex pays Bristol, Sanofi damages over Plavix
    Philadelphia Inquirer logo Philadelphia Inquirer 3 days ago

    TRENTON - A generic-drug maker has paid nearly $445 million to end a decadelong patent-infringement battle with two pharmaceutical heavyweights over the blood thinner Plavix. Apotex Corp. , Canada's biggest drugmaker, has paid Bristol-Myers Squibb Co. and

  8. Getty Images logo Getty Images 9 months ago
    YUBA COUNTY, CA - MAY 16: (L-R) Timon Seubert of Germany and riding for Team Netapp, Laszlo Bodrogi of France and riding for Team Type 1-Sanofi Aventis, James Driscoll of the USA and riding for Jamis-Sutter Home and Ben Jacques-Maynes of the USA and riding...

    YUBA COUNTY, CA - MAY 16: (L-R) Timon Seubert of Germany and riding for Team Netapp, Laszlo Bodrogi of France and riding for Team Type 1-Sanofi Aventis, James Driscoll of the USA and riding for Jamis-Sutter Home and Ben Jacques-Maynes of the USA and riding... View Photo »

  9. Inexpensive but people like other companies. I like Bristol-Myers Squibb (BMY) and Sanofi-Aventis (SNY) for yield.
    SOURCE: The Street 2 months ago
  10. Sanofi-aventis CFO Jérôme Contamine comments on Q1 2011 results
    YouTube Logo YouTube Videos 6 months ago
  11. Apotex pays Bristol, Sanofi damages over Plavix
    Deseret News logo Deseret News 3 days ago
    FILE - This July 28, 2006 file photo, shows the blood thinner medication Plavix, in New York. Apotex Corp., Canada's biggest drugmaker has paid Bristol-Myers Squibb Co. and Sanofi SA more than $442 million to end a decade-long patent infringement case over blockbuster blood thinner Plavix, the world's second-best-selling drug.

    TRENTON, N.J. — Just three months before the world's second-best-selling drug gets U.S. generic competition, a generic company has paid nearly $445 million to finally end a decadelong, twist-filled patent infringement battle with two heavyweight drugmake

  12. ADMINISTRATIVE LAW – Sanofi-Aventis U.S. LLC v. F.D.A.
    Thomson Reuters News & Insight 3 days ago

    In order to access Westlaw, JavaScript is required. This browser appears to have JavaScript disabled. Choose one of the following options: Follow the instructions below to enable JavaScript in your browser. Access Westlaw Text which provides the function

(What's this?)
  1. Are you a Publisher?

    We built Daylife.com using Daylife platform, which helps you be more efficient and creative with content. It's designed for publishers, editors, and developers to build better content-based sites, services, and apps for clients and audiences. Learn More »

About Sanofi-Aventis

Wikipedia

Sanofi-Aventis (Euronext: SAN, NYSE: SNY), headquartered in Paris, France, is a multinational pharmaceutical company. The company is the world's fourth largest pharmaceutical company. Sanofi-Aventis engages in the research, development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but... Full Article

Related Photos

CEO of the pharmaceutical group Sanofi-Aventis Chris Viehbacher delivers a speech during a press conference to present the 2010 annual financial results of the company, on February 09, 2011 in Paris.
Pause Play 1/18
prev
  1. CEO of the pharmaceutical group Sanofi-Aventis Chris Viehbacher delivers a speech during a press conference to present the 2010 annual financial results of the company, on February 09, 2011 in Paris. Getty Images logo Getty Images 10 months ago

    CEO of the pharmaceutical group Sanofi-Aventis Chris Viehbacher delivers a speech during a press conference to present the 2010 annual financial results of the company, on February 09, 2011 in Paris.

    View Photo »
  2. Gerard Le Fur, Chief Executive Officer of Sanofi-Aventis pharmaceutical group attends a press conference announcing the 2007 financial results of the French company, on February 12, 2008 in Paris. Getty Images logo Getty Images 10 months ago

    Gerard Le Fur, Chief Executive Officer of Sanofi-Aventis pharmaceutical group attends a press conference announcing the 2007 financial results of the French company, on February 12, 2008 in Paris.

    View Photo »
  3. Senior Executive Vice President of Sanofi Aventis, Gerard Le Fur, holds a press conference, 13 February 2007 in Paris, to present the 2006 results of the French pharmaceutical group. Getty Images logo Getty Images 10 months ago

    Senior Executive Vice President of Sanofi Aventis, Gerard Le Fur, holds a press conference, 13 February 2007 in Paris, to present the 2006 results of the French pharmaceutical group.

    View Photo »
  4. Pharmaceutical group Sanofi-Aventis' Chief Executive Jean-Francois Dehecq smiles addresses the group's general meeting in Paris 31 May 2006. Sanofi-Aventis chief executive Jean-Francois Dehecq said he will propose to nominate Senior Executive Vice President Gerard Le Fur to take over... Getty Images logo Getty Images 10 months ago

    Pharmaceutical group Sanofi-Aventis' Chief Executive Jean-Francois Dehecq smiles addresses the group's general meeting in Paris 31 May 2006. Sanofi-Aventis chief executive Jean-Francois Dehecq said he will propose to nominate Senior Executive Vice President Gerard Le Fur to take over...

    View Photo »
  5. Pharmaceutical French group Sanofi-Aventis chairman Jean-Francois Dehecq holds a press conference 24 February 2006 in Paris to present the full-year 2005 results. Sanofi-Aventis announced a series of positive drug research developments. Getty Images logo Getty Images 10 months ago

    Pharmaceutical French group Sanofi-Aventis chairman Jean-Francois Dehecq holds a press conference 24 February 2006 in Paris to present the full-year 2005 results. Sanofi-Aventis announced a series of positive drug research developments.

    View Photo »
  6. Pharmaceutical French group Sanofi-Aventis Gerard Le Fur, Executive Vice President for Scientific and Medical Operations, holds a press conference with Chairman Jean-Francois Dehecq (unseen) 24 February 2006 in Paris to present the full-year 2005 results. Sanofi-Aventis announced a... Getty Images logo Getty Images 10 months ago

    Pharmaceutical French group Sanofi-Aventis Gerard Le Fur, Executive Vice President for Scientific and Medical Operations, holds a press conference with Chairman Jean-Francois Dehecq (unseen) 24 February 2006 in Paris to present the full-year 2005 results. Sanofi-Aventis announced a...

    View Photo »
  7. Sanofi-Aventis CEO Chris Viehbacher, left, and Genzyme CEO, Henri Termeer react to a reporters question during a news conference at Genzyme's headquarters in Cambridge, Mass. , Wednesday, Feb. 16, 2011 to announce that the French drug maker agreed to buy Genzyme Corp. in an all-cash $20.1... AP Photo logo AP Photo 12 months ago

    Sanofi-Aventis CEO Chris Viehbacher, left, and Genzyme CEO, Henri Termeer react to a reporters question during a news conference at Genzyme's headquarters in Cambridge, Mass. , Wednesday, Feb. 16, 2011 to announce that the French drug maker agreed to buy Genzyme Corp. in an all-cash $20.1...

    View Photo »
  8. Sanofi-Aventis CEO Chris Viehbacher, left, and Genzyme CEO, Henri Termeer speak to reporters during a news conference at Genzyme's headquarters in Cambridge, Mass. , Wednesday, Feb. 16, 2011, to announce that The French drug maker agreed to buy Genzyme Corp. in an all-cash $20.1 billion... AP Photo logo AP Photo 12 months ago

    Sanofi-Aventis CEO Chris Viehbacher, left, and Genzyme CEO, Henri Termeer speak to reporters during a news conference at Genzyme's headquarters in Cambridge, Mass. , Wednesday, Feb. 16, 2011, to announce that The French drug maker agreed to buy Genzyme Corp. in an all-cash $20.1 billion...

    View Photo »
  9. SACRAMENTO, CA - MAY 16: (L-R) James Driscoll of the USA and riding for Jamis-Sutter Home leads the breakaway group infront of Laszlo Bodrogi of France and riding for Team Type 1-Sanofi Aventis, Ben Jacques-Maynes of the USA and riding for Bissell Cycling and Timon Seubert of Germany and... Getty Images logo Getty Images 9 months ago

    SACRAMENTO, CA - MAY 16: (L-R) James Driscoll of the USA and riding for Jamis-Sutter Home leads the breakaway group infront of Laszlo Bodrogi of France and riding for Team Type 1-Sanofi Aventis, Ben Jacques-Maynes of the USA and riding for Bissell Cycling and Timon Seubert of Germany and...

    View Photo »
  10. YUBA COUNTY, CA - MAY 16: (L-R) Timon Seubert of Germany and riding for Team Netapp, Laszlo Bodrogi of France and riding for Team Type 1-Sanofi Aventis, James Driscoll of the USA and riding for Jamis-Sutter Home and Ben Jacques-Maynes of the USA and riding for Bissell Cycling work together... Getty Images logo Getty Images 9 months ago

    YUBA COUNTY, CA - MAY 16: (L-R) Timon Seubert of Germany and riding for Team Netapp, Laszlo Bodrogi of France and riding for Team Type 1-Sanofi Aventis, James Driscoll of the USA and riding for Jamis-Sutter Home and Ben Jacques-Maynes of the USA and riding for Bissell Cycling work together...

    View Photo »
  11. France's Industry Minister Eric Besson (C) flanked by the president of French pharmaceutical giant Sanofi-Aventis in France, Christian Lajoux (L) and Lyon mayor, Gerard Collomb (R), visits the new vaccine manufacturing plant of the Pasteur Sanofi group on May 13, 2011, in Neuville-sur-Saône,... Getty Images logo Getty Images 9 months ago

    France's Industry Minister Eric Besson (C) flanked by the president of French pharmaceutical giant Sanofi-Aventis in France, Christian Lajoux (L) and Lyon mayor, Gerard Collomb (R), visits the new vaccine manufacturing plant of the Pasteur Sanofi group on May 13, 2011, in Neuville-sur-Saône,...

    View Photo »
  12. An Employee works on a vaccine assembly line on February 1, 2011 in the vaccine production factory of Sanofi-Pasteur, the vaccine branch of French pharmaceutical giant Sanofi-Aventis in Marcy-l'Etoile, outside Lyon. Sanofi-Aventis won control of giant US biotechnology group Genzyme on... Getty Images logo Getty Images 11 months ago

    An Employee works on a vaccine assembly line on February 1, 2011 in the vaccine production factory of Sanofi-Pasteur, the vaccine branch of French pharmaceutical giant Sanofi-Aventis in Marcy-l'Etoile, outside Lyon. Sanofi-Aventis won control of giant US biotechnology group Genzyme on...

    View Photo »
  13. A picture taken on February 16, 2011 in Saint-Germain-en-Laye, west of Paris shows the facade of the US biotechnology group Genzyme's French headquarters. French pharmaceutical giant Sanofi-Aventis won control of Genzyme after increasing its offer considerably in a drawn out battle. Getty Images logo Getty Images 12 months ago

    A picture taken on February 16, 2011 in Saint-Germain-en-Laye, west of Paris shows the facade of the US biotechnology group Genzyme's French headquarters. French pharmaceutical giant Sanofi-Aventis won control of Genzyme after increasing its offer considerably in a drawn out battle.

    View Photo »
  14. A pedestrian passes Genzyme's headquarters in Cambridge, Mass. , Wednesday,Feb. 16, 2011. The French drug maker Sanofi-Aventis SA agreed to buy Genzyme Corp. in an all-cash $20.1 billion deal after almost 9 months of negotiations. AP Photo logo AP Photo 12 months ago

    A pedestrian passes Genzyme's headquarters in Cambridge, Mass. , Wednesday,Feb. 16, 2011. The French drug maker Sanofi-Aventis SA agreed to buy Genzyme Corp. in an all-cash $20.1 billion deal after almost 9 months of negotiations.

    View Photo »
  15. An exhaust vent fogs the air outside Genzyme's headquartrers in Cambridge, Mass. , Wednesday,Feb. 15, 2011. The French drug maker Sanofi-Aventis SA agreed to buy Genzyme Corp. in an all-cash $20.1 billion deal after almost 9 months of negotiations. AP Photo logo AP Photo 12 months ago

    An exhaust vent fogs the air outside Genzyme's headquartrers in Cambridge, Mass. , Wednesday,Feb. 15, 2011. The French drug maker Sanofi-Aventis SA agreed to buy Genzyme Corp. in an all-cash $20.1 billion deal after almost 9 months of negotiations.

    View Photo »
  16. DILE - In this Feb. 15, 2011 file photo, Sanofi-aventis CEO Chris Viehbacher, left, responds to a reporter's question as Genzyme CEO Henri Termeer looks on during a news conference at Genzyme's headquartrers in Cambridge, Mass. France's Sanofi-Aventis SA said Monday March 7, 2011, it... AP Photo logo AP Photo 12 months ago

    DILE - In this Feb. 15, 2011 file photo, Sanofi-aventis CEO Chris Viehbacher, left, responds to a reporter's question as Genzyme CEO Henri Termeer looks on during a news conference at Genzyme's headquartrers in Cambridge, Mass. France's Sanofi-Aventis SA said Monday March 7, 2011, it...

    View Photo »
  17. A demonstrator wears a mask with French President Nicolas sarkozy's face, as employees of the French pharmaceutical group Sanofi-Aventi demonstrate against job cuts in front of the headquarters of the company on February 9, 2011 in Paris. French pharmaceutical group Sanofi-Aventis said... Getty Images logo Getty Images 12 months ago

    A demonstrator wears a mask with French President Nicolas sarkozy's face, as employees of the French pharmaceutical group Sanofi-Aventi demonstrate against job cuts in front of the headquarters of the company on February 9, 2011 in Paris. French pharmaceutical group Sanofi-Aventis said...

    View Photo »
  18. Employees of the French pharmaceutical group Sanofi-Aventi demonstrate against job cuts in front of the headquarters of the company on February 9, 2011 in Paris. French pharmaceutical group Sanofi-Aventis said today that it expected its earnings per share to slide by five to 10 percent... Getty Images logo Getty Images 12 months ago

    Employees of the French pharmaceutical group Sanofi-Aventi demonstrate against job cuts in front of the headquarters of the company on February 9, 2011 in Paris. French pharmaceutical group Sanofi-Aventis said today that it expected its earnings per share to slide by five to 10 percent...

    View Photo »
next
Getty Images logo Getty Images 10 months ago

CEO of the pharmaceutical group Sanofi-Aventis Chris Viehbacher delivers a speech during a press conference to present the 2010 annual financial results of the company, on February 09, 2011 in Paris.

View Photo »
View All »

Related Topics

  1. Bristol-Myers Squibb Bristol-Myers Squibb
  2. Genzyme Corporation Genzyme Corporation
  3. Merck & Company, Inc. Merck & Company, Inc.
  4. Pfizer Inc. Pfizer Inc.
  5. AstraZeneca PLC AstraZeneca PLC
  6. NYSE NYSE

Timeline of Coverage

  1. Click to see all coverage from Dec 27, 2011
    0
    December 27, 2011
  2. Click to see all coverage from Dec 28, 2011
    0
    December 28, 2011
  3. Click to see all coverage from Dec 29, 2011
    2
    December 29, 2011
  4. Click to see all coverage from Dec 30, 2011
    1
    December 30, 2011
  5. Click to see all coverage from Dec 31, 2011
    0
    December 31, 2011
  6. Click to see all coverage from Jan 01, 2012
    0
    January 01, 2012
  7. Click to see all coverage from Jan 02, 2012
    0
    January 02, 2012
  8. Click to see all coverage from Jan 03, 2012
    2
    January 03, 2012
  9. Click to see all coverage from Jan 04, 2012
    0
    January 04, 2012
  10. Click to see all coverage from Jan 05, 2012
    2
    January 05, 2012
  11. Click to see all coverage from Jan 06, 2012
    0
    January 06, 2012
  12. Click to see all coverage from Jan 07, 2012
    0
    January 07, 2012
  13. Click to see all coverage from Jan 08, 2012
    1
    January 08, 2012
  14. Click to see all coverage from Jan 09, 2012
    0
    January 09, 2012
  15. Click to see all coverage from Jan 10, 2012
    0
    January 10, 2012
  16. Click to see all coverage from Jan 11, 2012
    3
    January 11, 2012
  17. Click to see all coverage from Jan 12, 2012
    1
    January 12, 2012
  18. Click to see all coverage from Jan 13, 2012
    0
    January 13, 2012
  19. Click to see all coverage from Jan 14, 2012
    0
    January 14, 2012
  20. Click to see all coverage from Jan 15, 2012
    0
    January 15, 2012
  21. Click to see all coverage from Jan 16, 2012
    0
    January 16, 2012
  22. Click to see all coverage from Jan 17, 2012
    6
    January 17, 2012
  23. Click to see all coverage from Jan 18, 2012
    4
    January 18, 2012
  24. Click to see all coverage from Jan 19, 2012
    0
    January 19, 2012
  25. Click to see all coverage from Jan 20, 2012
    0
    January 20, 2012
  26. Click to see all coverage from Jan 21, 2012
    0
    January 21, 2012
  27. Click to see all coverage from Jan 22, 2012
    0
    January 22, 2012
  28. Click to see all coverage from Jan 23, 2012
    0
    January 23, 2012
  29. Click to see all coverage from Jan 24, 2012
    0
    January 24, 2012
  30. Click to see all coverage from Jan 25, 2012
    0
    January 25, 2012
  31. Click to see all coverage from Jan 26, 2012
    2
    January 26, 2012
  32. Click to see all coverage from Jan 27, 2012
    0
    January 27, 2012
  33. Click to see all coverage from Jan 28, 2012
    0
    January 28, 2012
  34. Click to see all coverage from Jan 29, 2012
    0
    January 29, 2012
  35. Click to see all coverage from Jan 30, 2012
    0
    January 30, 2012
  36. Click to see all coverage from Jan 31, 2012
    1
    January 31, 2012
  37. Click to see all coverage from Feb 01, 2012
    1
    February 01, 2012
  38. Click to see all coverage from Feb 02, 2012
    0
    February 02, 2012
  39. Click to see all coverage from Feb 03, 2012
    1
    February 03, 2012
  40. Click to see all coverage from Feb 04, 2012
    0
    February 04, 2012
  41. Click to see all coverage from Feb 05, 2012
    0
    February 05, 2012
  42. Click to see all coverage from Feb 06, 2012
    0
    February 06, 2012
  43. Click to see all coverage from Feb 07, 2012
    2
    February 07, 2012
  44. Click to see all coverage from Feb 08, 2012
    4
    February 08, 2012
  45. Click to see all coverage from Feb 09, 2012
    1
    February 09, 2012
  46. Click to see all coverage from Feb 10, 2012
    2
    February 10, 2012
  47. Click to see all coverage from Feb 11, 2012
    0
    February 11, 2012
  48. Click to see all coverage from Feb 12, 2012
    0
    February 12, 2012

Related Videos

  1. Videosurf
    1. Capstone's Shah Discusses Sanofi-Aventis Bid for Genzyme : Video
      Capstone's Shah Discusses Sanofi-Aventis Bid fo...
    2. Managing Nasal Allergies - Video
      Managing Nasal Allergies - Video
    3. SQUAWK BOX EUROPE : Sanofi-Aventis CEO on Genzyme Bid
      SQUAWK BOX EUROPE : Sanofi-Aventis CEO on Genzy...
      12 months ago
    4. power lunch : Sanofi-Aventis Q1 Profits Up
      power lunch : Sanofi-Aventis Q1 Profits Up
      21 months ago
    5. Sanofi-Aventis : A Good Buy?
      Sanofi-Aventis : A Good Buy?
      14 months ago
    6. Sanofi-Aventis CEO on Strategy
      Sanofi-Aventis CEO on Strategy
      36 months ago
    View All Videosurf Videos »

Related Quotes

  • Previous
  • Next
  • 1/5
  1. This is one of those treatments that have been tossed around like a hot potato for the past decade or more ... For example, some rights to DiaPep277 were acquired by the company known as Aventis (which became Sanofi Aventis back in 1997), although full rights were reported to be acquired by the predeces...
    SOURCE: Diabetes Mine 3 weeks ago
  2. Inexpensive but people like other companies. I like Bristol-Myers Squibb (BMY) and Sanofi-Aventis (SNY) for yield.
    SOURCE: The Street 2 months ago
  3. one of the slower growers and I don't want to be there. I prefer Celgene (NASDAQ: CELG) or Sanofi-Aventis (NYSE: SNY).
    SOURCE: Benzinga.com 2 months ago
  4. That's one of the slower growers and I don't want to be there. I prefer Celgene (CELG) or Sanofi-Aventis (SNY).
    SOURCE: The Street 2 months ago
  5. It's OK. I prefer Sanofi-Aventis (SNY) or Abbott Laboratories (ABT) or Bristol-Myers Squibb (BMY).
    SOURCE: The Street 2 months ago
View All »